The value of the drugmaker Novo Nordisk jumped by about £9bn on Thursday after research showed that taking its new anti-obesity pill can result in almost as much weight loss as its Wegovy jab. Shares in Novo Nordisk climbed by more than 6 percent on hopes that it can claw back market share lost to Eli Lilly and cheaper generic versions of GLP-1 drugs. The Danish company is going head to head with Lilly’s daily weight loss pill, called orforglipron. ADVERTISEMENTThe shares of GLP-1 drugmakers have vastly outperformed pharmaceutical companies that do not make those weight loss drugs. By Julia KolleweLearn more:Ozempic Maker Novo Nordisk Slashes 9,000 JobsThe Danish pharmaceutical giant announced it would shed 11.5 percent of its workforce to reignite growth and fend off competition in the GLP-1 weight loss drug wars.